Match tier Listed
Presence Current · Arkansas
Last published 2024
Sources OpenAlex · ORCID
Refreshed 2026-08-08

R. Eric Davis

Medical Student

Faculty Researcher

1 h-index 15 pubs 8 cited

  • Glutaminase
  • Lung Neoplasms
  • Apoptosis
  • Benzeneacetamides
  • Antineoplastic Agents
  • Cell Survival
  • Glutamine
  • Humans
  • Thiadiazoles
  • Cell Line, Tumor
  • Cell Proliferation

Biography and Research Information

OverviewAI-generated summary

R. Eric Davis, a medical student at the University of Arkansas for Medical Sciences, has research interests focused on cancer biology and therapeutics. His recent work includes a 2024 publication investigating the effects of CB-839 on lung tumor cells, exploring its potential to induce reversible dormancy. Davis has also contributed to studies examining strategies to overcome resistance to venetoclax in aggressive B-cell lymphomas, with several publications in 2023 detailing supplementary figures and tables related to this research.

His scholarship metrics include an h-index of 1, with 15 total publications and 6 total citations. Davis collaborates with researchers at his institution, including Ruud P.M. Dings, Eric R. Siegel, Gunnar Boysen, and Azemat Jamshidi‐Parsian, with whom he has shared publications. His work is characterized by an active research presence, with his most recent publication in 2024.

Metrics

  • h-index: 1
  • Publications: 15
  • Citations: 8

Selected Publications

  • CB-839 induces reversible dormancy in lung tumor-cells (2024)
    European Journal of Pharmacology 8 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

9 Collaborators 1 Institution 1 Country

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics